Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William G Kramer

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Clinical Pharmacology in Drug Development|December 3, 2017
Pharmacokinetics of Diclofenac and Hydroxypropyl-β-Cyclodextrin (HPβCD) Following Administration of Injectable HPβCD-Diclofenac in Subjects With Mild to Moderate Renal Insufficiency or Mild Hepatic ImpairmentDouglas A Hamilton, Cynthia C Ernst, William G Kramer, et al.
Clinical Pharmacology : Advances and Applications|December 24, 2016
A Phase I study evaluating the effect of age and weight on the pharmacokinetics of an injectable formulation of diclofenac solubilized with hydroxypropyl-β-cyclodextrinRonald Goldwater, William G Kramer, Douglas A Hamilton, et al.
Journal of Clinical Pharmacology|September 25, 2010
Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteersM Judith Peterschmitt, Amy Burke, Larry Blankstein, et al.
Antimicrobial Agents and Chemotherapy|March 29, 2023
Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy VolunteersMichael R Hodges, Eric Ople, Pamela Wedel, et al.
Clinical Ophthalmology (Auckland, N.Z.)|May 2, 2019
A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteersPaul M Karpecki, Sidney L Weiss, William G Kramer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2004
Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteersRobert J Hopkins, William G Kramer, William C Blackwelder, et al.
Steroids|March 11, 2018
Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomesEric P Hoffman, Valerie Riddle, Maxime A Siegler, et al.
International Immunopharmacology|March 10, 2009
Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adultsLeonard E Weisman, Gerald W Fischer, Helen M Thackray, et al.
Antimicrobial Agents and Chemotherapy|April 22, 2009
Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonatesLeonard E Weisman, Helen M Thackray, Joseph A Garcia-Prats, et al.
Antimicrobial Agents and Chemotherapy|August 28, 2013
Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthraxNutan Mytle, Robert J Hopkins, Nina V Malkevich, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Clinical Pharmacology in Drug Development|December 3, 2017
Pharmacokinetics of Diclofenac and Hydroxypropyl-β-Cyclodextrin (HPβCD) Following Administration of Injectable HPβCD-Diclofenac in Subjects With Mild to Moderate Renal Insufficiency or Mild Hepatic ImpairmentDouglas A Hamilton, Cynthia C Ernst, William G Kramer, et al.
Clinical Pharmacology : Advances and Applications|December 24, 2016
A Phase I study evaluating the effect of age and weight on the pharmacokinetics of an injectable formulation of diclofenac solubilized with hydroxypropyl-β-cyclodextrinRonald Goldwater, William G Kramer, Douglas A Hamilton, et al.
Journal of Clinical Pharmacology|September 25, 2010
Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteersM Judith Peterschmitt, Amy Burke, Larry Blankstein, et al.
Antimicrobial Agents and Chemotherapy|March 29, 2023
Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy VolunteersMichael R Hodges, Eric Ople, Pamela Wedel, et al.
Clinical Ophthalmology (Auckland, N.Z.)|May 2, 2019
A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteersPaul M Karpecki, Sidney L Weiss, William G Kramer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2004
Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteersRobert J Hopkins, William G Kramer, William C Blackwelder, et al.
Steroids|March 11, 2018
Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomesEric P Hoffman, Valerie Riddle, Maxime A Siegler, et al.
International Immunopharmacology|March 10, 2009
Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adultsLeonard E Weisman, Gerald W Fischer, Helen M Thackray, et al.
Antimicrobial Agents and Chemotherapy|April 22, 2009
Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonatesLeonard E Weisman, Helen M Thackray, Joseph A Garcia-Prats, et al.
Antimicrobial Agents and Chemotherapy|August 28, 2013
Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthraxNutan Mytle, Robert J Hopkins, Nina V Malkevich, et al.
Pageof 4